Literature DB >> 17245797

Identification of abacavir hypersensitivity reaction in health care claims data.

Beth L Nordstrom1, Heather S Norman, Timothy J Dube, Marsha A Wilcox, Alexander M Walker.   

Abstract

PURPOSE: Abacavir is associated with an infrequent but potentially serious hypersensitivity reaction (HSR) that can include a wide range of signs and symptoms. Identification of this reaction through medical insurance claims could provide a simple and efficient means of monitoring the incidence of abacavir hypersensitivity in large populations of patients.
METHODS: Using data from a safety study of 948 abacavir users with 22 hypersensitivity events identified from claims and validated through medical record review, we used a recursive partitioning analysis to construct an algorithm to differentiate between patients with and without validated adverse events. Bootstrap resampling techniques provided validation for the analysis.
RESULTS: The analysis produced a classification tree with three decision nodes that comprised the best indicators of HSRs. The predictors included any one of several specific symptoms commonly found with this reaction, a claims diagnosis of adverse effect of drug, anaphylactic shock or unspecified allergy, and a discontinuation in abacavir prior to completing a 90-day course of therapy. The algorithm demonstrated 95% sensitivity and 90% specificity when tested using a bootstrap resampling approach with the current data.
CONCLUSIONS: A sensitive and specific algorithm for identifying abacavir hypersensitivity from claims was created. This algorithm would permit efficient identification of charts for medical review. Further testing of the algorithm with additional medical claims data for abacavir users will be required to ascertain its validity across databases. (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17245797     DOI: 10.1002/pds.1337

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  4 in total

1.  Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV.

Authors:  Teresa L Kauf; Raymond A Farkouh; Stephanie R Earnshaw; Maria E Watson; Penny Maroudas; Mike G Chambers
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

2.  Tradeoffs between accuracy measures for electronic health care data algorithms.

Authors:  Jessica Chubak; Gaia Pocobelli; Noel S Weiss
Journal:  J Clin Epidemiol       Date:  2011-12-23       Impact factor: 6.437

3.  The Validity of Claims-Based Algorithms to Identify Serious Hypersensitivity Reactions and Osteonecrosis of the Jaw.

Authors:  Nicole C Wright; Jeffrey R Curtis; Tarun Arora; Wilson K Smith; Meredith L Kilgore; Kenneth G Saag; Monika M Safford; Elizabeth S Delzell
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

4.  Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab.

Authors:  K A Foley; P F Wang; B L Barber; S R Long; J E Bagalman; V Wagner; X Song; Z Zhao
Journal:  Ann Oncol       Date:  2010-01-25       Impact factor: 32.976

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.